Biogen Prepares More Doubtful Phase III Results For FDA Scrutiny, This Time In ALS

Will Hope To Ride On Coattails Of Amylyx’s Thumbs Up

 
• By Andrew McConaghie
  
Biogen
Even if approved, tofirsen looks unlikely to be a big earner for Biogen, which is depending on other late-stage candidates to revive its fortunes.
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

More from R&D